| Systemic Lupus Erythematosus |
1 |
1 |
| Lupus |
0 |
0.89 |
| Cutaneous Lupus Erythematosus |
0 |
0.98 |
| Arthritis |
0 |
0.23 |
| Biologic Therapy |
0 |
0.21 |
| Rheumatoid Arthritis |
0 |
0.15 |
| Cytokines |
0 |
0.14 |
| Dermatoses |
0 |
0.14 |
| Hospital |
0 |
0.14 |
| Humanized Monoclonal Antibody |
0 |
0.99 |
| Antigens |
0 |
0.09 |
| Blood |
0 |
0.09 |
| Europe |
0 |
0.09 |
| Monoclonal Antibody |
0 |
0.09 |
| New York |
0 |
0.09 |
| Skin Lesion |
0 |
0.09 |
| Surgery |
0 |
0.09 |
| Board Certification |
0 |
0.05 |
| Chemokine Receptor |
0 |
0.05 |
| Chemokines |
0 |
0.05 |
| Diversity |
0 |
0.05 |
| Drug Development |
0 |
0.05 |
| Glucocorticoid |
0 |
0.05 |
| Pathogenesis |
0 |
0.05 |
| Receptors |
0 |
0.05 |
| Severity Index |
0 |
0.05 |
| Tumor |
0 |
0.05 |
| Healthcare and Medical Technology |
0 |
0.04 |
| Social Determinants of Health |
0 |
0.04 |
| Vasculitis |
0 |
0.04 |